# 1. Financial Performance ## A. Key Figures * **Operating Revenue:** **₹5 Cr** Q2 FY'26 (+48% YoY, +6% QoQ) * **EBITDA:** **₹2 Cr** Q2 FY'26 (+298% YoY, +28% QoQ) ## B. Revenue Growth * **Accurate Revenue Recognition:** Revenue and cost recognition are aligned, with no overstatement in the current quarter. ## C. EBITDA Margins * **Strong Margin Expansion:** EBITDA margin surge driven by improved product mix, higher operating leverage, and declining unabsorbed costs amid **near-full plant occupancy**. * **Pricing Power Preserved:** Upcoming raw material cost increases expected to be passed through, supporting **sustained margin improvement**. ## D. ROCE Trends * **ROCE Pressure from Capital Intensity:** Low pre-tax ROCE of 4% in H1 FY'26 reflects increased capital intensity in multistage chemistry, with revenue-to-investment ratio worsening from 1:3 to 1:1–5. * **EBIT Focus for ROCE:** Management emphasizes ROCE is calculated on **EBIT**, not EBITDA, with ₹25 Cr EBIT generated on ₹680 Cr capital employed. --- # 2. Product & Segment Performance ## A. Key Figures * SDA Revenue: ₹593 Mn Structure Directing Agents (+119% YoY) · ₹293 Mn Phase Transfer Catalysts (+7% YoY) * Electrolyte Salts Revenue: ₹12 million (+47% QoQ, -5% YoY) * Pharma, Agro & Specialty Chemicals Revenue: ₹324 Mn (-31% QoQ, +19% YoY) * **Pharma Intermediates Revenue:** ₹1–2 Cr (current quarter) ## B. SDA Segment * **Breakout Growth in Structure Directing Agents:** SDA segment shows strong recovery with robust double-digit year-on-year revenue surge, driven by innovation and favorable macro trends in hybrid vehicles. * **Macro Tailwinds Amplify Demand:** Rising global demand for non-EV and hybrid vehicles, coupled with upcoming **Euro 7 emission standards**, is fueling volume growth and pricing power across SDA products. * **Sustained Momentum with New Commercial Scale-Ups:** Plant-scale deliveries underway for semiconductor chemicals; **three commercial batches** targeted for delivery by **Q4**, marking strategic expansion beyond core SDA. * **Durable Competitive Advantage:** Shift from commoditized PTC to proprietary SDA in 2015 has proven successful—**no Indian competitor in 10 years**—validating technology-led differentiation strategy. ## C. Electrolyte Salts * **Emerging Growth Engine with Scaling Visibility:** Despite YoY decline, sequential growth reflects increasing adoption in energy storage and hybrid vehicle supercapacitors, with **weekly dispatches** now established. * **Clear Path to Commercialization:** Revenue expected to reach **INR15 Cr** this fiscal, with **INR20–25 Cr** projected in FY '27 as new products move toward full commercialization. * **Tariff Headwinds Delay Expansion:** **Trump-era reciprocal tariffs** adding nearly **50% duties** are delaying commercialization of a new ESS electrolyte product; policy change could unlock significant upside. ## D. Pharma Intermediates * **Near-Term Revenue Pipeline Building:** Two campaigns underway—**INR2–3 Cr** expected in Q3, followed by a **INR12–13 Cr** order in December–January—marking initial scaling of commercialized products. * **High Future Potential Despite Small Base:** Segment currently contributes minimally to revenue but holds **INR300–350 Cr** total addressable potential across 7–8 molecules, justifying standalone tracking. ## E. Agrochemical Products * **New Product Launches Accelerate Monetization:** Two new **agro intermediates** for herbicides and insecticides to be commercialized in **Q3**, with one holding **INR200 Cr revenue potential** subject to capex. * **Technology-Driven Edge in Challenging Market:** Despite industry-wide volume constraints, proprietary processes enable **decent volumes** and support early commercialization of complex, cost-efficient agrochemicals. --- # 3. Capacity & Utilization ## A. Key Figures * **Plant Utilization:** **50%** SDA plant · **~80%** other plant * **Batch Size Scaling:** From **2 tons to 5 tons** ## B. Plant Occupancy * **Divergent Utilization:** SDA plant operates at moderate utilization, while the remainder of the facility runs near full capacity with improved productivity. * **PASC Segment Dynamics:** Despite revenue recognition delays, high plant occupancy and rising productivity signal underlying operational strength. ## C. New Facility Progress * **Capacity Expansion On Track:** New plant block on schedule for commercial launch by January 2026, set to alleviate bottlenecks in agro and pharma intermediates. * **Strategic Product-Led Growth:** Dedicated plant in design for a high-demand agro intermediate; another **single product with revenue potential equal to current Tatva total** will drive new construction at Jolva by early 2026. ## D. Batch Scaling Plans * **Phased Volume Ramp-Up:** Initial conservative order management to ensure reliability, with scaling expected from June onward. * **Operational Optimization:** Scaling to include larger batch runs and multi-site trials across Ankleshwar, Dahej, and prospective Jolva facility. --- # 4. R&D & Commercialization ## A. Key Figures * **Commercialization Timeline:** First commercial supply under green chemistry initiative in **Q3**, customer delivery by **early to mid-November** * **Product Pipeline:** **Four pharma** and **four agro intermediates** in development, with full potential expected within **2–3 years** * **Regulatory Milestone:** **DMF filing** for pharma products pending, to be completed by **June** post-validation ## B. Pilot to Commercial * **Commercial Traction in Hybrid Vehicles:** First small-scale commercial order completed with hybrid vehicle battery manufacturer; positive feedback received, with full commercialization expected in **2026** * **Pharma Intermediates Advancing:** Three new pharma intermediates on track for commercialization between **December 2025 and H2 2026**, supported by smooth validation batches; one additional opportunity in development * **Semiconductor Chemicals Gaining Momentum:** Pilot-scale deliveries confirm process robustness; progressing to full-scale commercial plant trial material, with commercialization expected by **end-2027/early 2028** despite initially insignificant revenues * **Agro Intermediates with Domestic Upside:** Validation ongoing for high-potential agro intermediate; positioned as a key product for the new **Jolva greenfield facility**; initial samples to customers expected before **end-December** * **Innovation-Driven Product Selection:** Management emphasizes pursuing only differentiated, innovative products that secure **sustainable margins** at scale ## C. Green Chemistry Initiatives * **Sustainable Edge in Development:** Green chemistry platform delivering cost-efficient, eco-friendly catalytic processes; underpins pipeline expansion and deeper customer partnerships * **Margin Profile Supported by Design:** New products, like current offerings, expected to carry **superior margins** due to embedded innovation and sustainability features --- # 5. Customer & Supply Chain ## A. Supply Chain Validation * **Pending Commercial Recognition:** Exported PASC goods not yet reflected in sales, creating a temporary disconnect between high production and low reported revenue due to ongoing supply chain validation expected to conclude by **June**. * **Dossier-Based, Non-Proprietary Model:** Products are dossier-based with regulatory involvement by Tatva, but **patents retained by MNC customers**, limiting IP ownership. ## B. Customer Onboarding * **BS6-Driven Volume Inflection:** BS6 implementation to catalyze incremental volume growth, with meaningful customer onboarding anticipated from **2026**. * **Early-Stage Adoption in New Segments:** Trial-phase engagements underway for **energy shield** and advanced battery materials, signaling initial market penetration into high-growth applications. ## C. Import Dependency * **High Import Reliance, No Tariff Exposure:** Approximately **40–45% of raw materials imported**, with limited domestic sourcing; however, no products currently subject to reciprocal duties. * **Competitive Supplier Landscape:** Operates in a multi-supplier global environment with **two or three key players** per product line, including potential parallel supply chains in **China and Europe**; not a sole or exclusive supplier. --- # 6. Technology & Innovation Risks ## A. Multistage Chemistry * **Production Bottlenecks:** Certain PASC segment products face inefficiencies due to **lack of specific plant amenities**, impacting process recovery and reuse. * **Technical Learning Curve:** Multistage chemistry represents a new capability with a **~6-month adaptation period** required to achieve stable operations. * **First-Mover Advantage:** Two semiconductor products in piloting involve **novel, non-competitive molecules**, positioning the company as the **potential unique global supplier** post-commercialization. * **ROCE Pressure:** Low returns currently driven by **low plant occupancy** and **high CapEx intensity** from complex, multistep chemistries in new agro and pharma intermediates. * **Specialized Role in Pharma Chain:** Tatva operates at **stages 4 to 6** of the API synthesis pathway, focusing on complex, later-stage intermediates within a fragmented value chain. ## B. Process Scalability * **High-Barrier Focus Areas:** Strategic emphasis on **electrolyte salt and semiconductor products** with **extremely difficult replication** and **high entry barriers**, ensuring durable competitive advantage. --- # 7. Guidance & Outlook ## A. Key Figures * **Electrolyte Salt Revenue Target:** **10% of total revenue** by FY '27 * **Semiconductor Product Revenue:** **INR50–100 Cr** per product * **Hybrid Batteries & Advanced Materials Revenue Potential:** **INR300–350 Cr** from current molecules * **Full-Capacity Plant Revenue:** **INR800–850 Cr** * **Target EBITDA at Full Capacity:** **INR175 Cr** ## B. Revenue Projections * **Cyclical Rebound Underway:** Chemical industry shift from destocking to restocking supports cautious optimism, despite geopolitical and tariff headwinds. * **Long-Term Growth Trajectory:** Strategic initiatives driving tangible results, with Phase Transfer Catalysts maintaining leadership and steady organic growth. * **New Product Ramp-Up:** Full commercialization expected gradually, with meaningful business outcomes anticipated within **2 to 3 years**; hybrid batteries to begin slow commercialization by **2026**. * **Breakout Year Ahead:** **2027** projected as a transformational year, driven by fully optimized capacities and strong volume execution. ## C. Margin Targets * **Margin Expansion in Sight:** Target EBITDA margin of **20–22%** expected upon full plant occupancy, projected within the next two quarters. * **Profitability Leverage:** Rising utilization to drive higher ROCE and margins, underpinned by innovation-led differentiation rather than cost competition. ## D. CapEx Plans * **Growth-Focused Investment:** CapEx prioritized toward capacity expansion, timely new product commercialization, and advanced technology development.